Cleveland Clinic nets federal funds for research facility revamp

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 6
Volume 19
Issue 6

The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.


DEREK RAGHAVEN, MD, PHD

The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.

The funds will be used to update 3,600 square feet of laboratory space that was built on the clinic's main campus in 1928. The space was last renovated in the 1950s. Renovations will include a shared instrumentation room that will free up an additional 500 square feet to allow for more bench research.

The expanded laboratory area also will allow for the recruitment of up to four new independent researchers, a dozen technical support positions, and an administrative assistant.

"The expansion of our translational cancer research capabilities is essential to the mission of the Taussig Cancer Institute," said Derek Raghavan, MD, PhD, chair of the institute, in a written statement. "This award will allow us to continue to bring the latest research straight from the lab to the bedside to aid in the diagnosis and treatment of patients."

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content